Table 1 Characteristics of randomized clinical trials investigating the role of blood pressure lowering on stroke recurrence.
Study | Year | Drug | Type of Stroke | Subjects (Treated, Control) | Mean Follow-up Period (years) | Decrease in BP with Treatment (sys/dia in mmHg) |
|---|---|---|---|---|---|---|
BPLPRS [23] | 2005 | Perindopril + indapamide vs. placebo | TIA, Isch, Hem | 1520 (762, 758) | 4 | 14/6 |
Dutch TIA [20] | 1993 | Atenolol vs. placebo | TIA or non-disabling Isch | 1473 (732, 741) | 2.6 | 5.8/2.9 |
HOPE [33] | 2000 | Ramipril vs. placebo | TIA or stroke NS | 1013 (500, 513) | 5 | NS |
HSCSG [18] | 1974 | Deserpidine + methyclothiazide vs. placebo | TIA, Isch, Hem | 452 (233, 219) | 2.8 | 25/12.3 |
Martà Massó [19] | 1990 | Nicardipine vs. nothing | TIA, RIND, Isch | 264 (170, 94) | 1 | NS |
PATS [21] | 1995 | Indapamide vs. placebo | TIA, Isch, Hem | 5665 (2841, 2824) | 2.8 | 6.2/2.9 |
PRoFESS [13] | 2008 | Telmisartan vs. placebo | Isch | 20332 (10146, 10186) | 2.5 | 3.8/2 |
PROGRESS [10] | 2001 | Perindopril + indapamide OR perindopril vs. placebo | TIA, Isch, Hem | 6105 (3051, 3054) | 4 | 9/4 |
| Â | Â | Perindopril vs. placebo | Â | 2561a (1281, 1280) | Â | 5/3 |
| Â | Â | Perindopril + indapamide vs. placebo | Â | 3544a (1770, 1774) | Â | 12/5 |
SCOPE [24] | 2005 | Candesartan vs. placebo | NS | 193 (96, 97) | 3.7 | -0.4/1.5b |
TEST [22] | 1995 | Atenolol vs. placebo | NS | 720 (372, 348) | 2.5 | 4/3 |